Puetz J J, Bouhasin J D
Hemophilia Treatment Center, Cardinal Glennon Children's Hospital, St. Louis University Health Sciences Center, St. Louis, MO 63104, USA.
Haemophilia. 2001 Mar;7(2):215-9. doi: 10.1046/j.1365-2516.2001.00493.x.
A frequently encountered complication of therapy given to patients with severe haemophilia A is the development of antibodies to infused factor VIII. While much less common, inhibitors also occur in patients with mild or moderate severity haemophilia A. Often thought to be of low titre and transient, several cases of high-titre inhibitors have been described in patients with mild or moderate haemophilia A. Generally these occur in adults or adolescents following significant infused factor VIII exposure. A review of reported cases revealed only two cases of high-titre inhibitor formation in mild haemophilia A patients younger than 10 years of age. We wish to report our experience with an additional two children with mild haemophilia A and high titre inhibitors, and offer suggestions for the management of these children.
给予重度甲型血友病患者治疗时常见的并发症是产生针对输入的凝血因子 VIII 的抗体。虽然在轻度或中度甲型血友病患者中抑制剂的出现要少得多，但也有发生。通常认为其滴度较低且为一过性，但已有数例轻度或中度甲型血友病患者出现高滴度抑制剂的报道。一般来说，这些情况发生在成年或青少年患者大量输入凝血因子 VIII 之后。对已报道病例的回顾显示，10 岁以下轻度甲型血友病患者中仅有两例出现高滴度抑制剂形成。我们希望报告另外两名患有轻度甲型血友病和高滴度抑制剂的儿童的情况，并为这些儿童的管理提供建议。
